Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune-Checkpoint Blockade Therapy in Lymphoma
Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5456-5456
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 308
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 113
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Guoqiang Sun, Dawei Rong, Zhouxiao Li, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 72
Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics
Lili Zhou, Manshu Zou, Yilin Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 49
Aurora A kinase inhibition elevates PD-L1 expression and compromises its anti-tumor efficacy
Xiaobo Wang, Jing Huang, Fenglin Liu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 9
Open Access | Times Cited: 22
Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Haris Hatic, Devi Sampat, Gaurav Goyal
Annals of Translational Medicine (2021) Vol. 9, Iss. 12, pp. 1037-1037
Open Access | Times Cited: 52
Nanodrug Delivery Systems in Antitumor Immunotherapy
Zishuo Guo, Jinhong Ye, Xuehao Cheng, et al.
Biomaterials Research (2024) Vol. 28
Open Access | Times Cited: 7
Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review
Hongyu Gong, Siew Chin Ong, Li Fan, et al.
Health Economics Review (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
The future of immunotherapy for diffuse large B‐cell lymphoma
Johannes Duell, Jason R. Westin
International Journal of Cancer (2024) Vol. 156, Iss. 2, pp. 251-261
Open Access | Times Cited: 5
Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
Wenzhao Li, Wisam Najdawi, Omar Badla, et al.
Seminars in Ophthalmology (2025), pp. 1-11
Closed Access
A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021
Rina Sa, Yi Xu, Xinbo Pan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
Lin Yang, Qiuling Zhao, Ting Chen, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 7, pp. 3767-3780
Closed Access | Times Cited: 9
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Vincent Ribrag, Seung‐Tae Lee, David A. Rizzieri, et al.
Clinical Lymphoma Myeloma & Leukemia (2020) Vol. 21, Iss. 5, pp. 309-317.e3
Closed Access | Times Cited: 24
Prospects and Challenges for T Cell-Based Therapies of HCC
Norman Woller, Sophie Anna Engelskircher, Thomas Wirth, et al.
Cells (2021) Vol. 10, Iss. 7, pp. 1651-1651
Open Access | Times Cited: 21
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma
Houshi Xu, Anke Zhang, Chaoyou Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies
Luca Guarnera, Carlos Bravo‐Pérez, Valeria Visconte
Bioengineering (2023) Vol. 10, Iss. 10, pp. 1228-1228
Open Access | Times Cited: 8
Screening and identification of an anti-PD-1 nanobody with antitumor activity
Yanting Zhang, Shaoqi Yang, Dan Jiang, et al.
Bioscience Reports (2022) Vol. 43, Iss. 1
Open Access | Times Cited: 11
Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
Mandana AmeliMojarad, Melika AmeliMojarad, Xiaonan Cui
Pathology - Research and Practice (2023) Vol. 244, pp. 154338-154338
Closed Access | Times Cited: 6
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Robert Pytlík, Kamila Polgárová, Jana Karolová, et al.
Vaccines (2020) Vol. 8, Iss. 4, pp. 708-708
Open Access | Times Cited: 15
MeImmS: Predict Clinical Benefit of Anti-PD-1/PD-L1 Treatments Based on DNA Methylation in Non-small Cell Lung Cancer
Shipeng Shang, Xin Li, Yue Gao, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 12
Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study
Guozhen Yang, Yutong Hong, Xiaomin Zhang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 1
BANF1 is a novel prognostic biomarker linked to immune infiltration in head and neck squamous cell carcinoma
Yaodong He, Huan Li, Jing Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer
Lincheng Li, Jing Wang, Zhuochao Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape
Sara Ebrahimi, Adrina Habibzadeh, Soroush Khojasteh-Kaffash, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104225-104225
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top